Nurix Therapeutics, INC 10-Q quarterly reports

Nurix Therapeutics filed its Form 10-Q for the quarter ended May 31, 2026, detailing significant operating expenses and a net loss, while highlighting ongoing clinical trials and strategic collaborations.

Nurix Therapeutics, Inc. reported a net loss of $87.2 million for the three months ended February 28, 2026, with collaboration revenue decreasing to $6.3 million.

Nurix Therapeutics reported increased net losses in Q3 2025 driven by accelerated R&D spending on its clinical pipeline, while securing significant license revenue from Sanofi.

Nurix Therapeutics, a clinical-stage biopharmaceutical company, reported a significant increase in total revenue driven by new license agreements, alongside a substantial rise in research and development expenses leading to increased net losses, while advancing its lead drug candidates and securing key regulatory designations.

Nurix Therapeutics reports its financial results for the quarter ended February 28, 2025, and provides an update on its clinical development programs and collaborations.

Nurix Therapeutics' third quarter 2024 results show a net loss of $48.9 million, with collaboration revenue of $12.5 million, and significant progress in clinical development.

Nurix Therapeutics reports a net loss of $44.5 million for the three months ended May 31, 2024, while collaboration revenue increased to $12.1 million.

Nurix Therapeutics reports a net loss of $41.5 million for the first quarter of 2024, with collaboration revenue increasing to $16.6 million.